Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1983

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Multinational comparative clinical trial of long-acting injectable

contraceptives: norethisterone enanthate given in two dosage regimens and

depot-medroxyprogesterone acetate: final report.

AUTHORS

World Health Organization [WHO]. Special Programme of Research, Development

and Research Training in Human Reproduction. Task Force on Long-Acting

Systemic Agents for Fertility Regulation

SOURCE

[Unpublished] [1983]. 21 p.

ABSTRACT

Final results are presented from a 2-year World Health Organization multinational comparative trial of 3 regimens:

depot-medroxyprogesterone acetate (DMPA) given at 90-day intervals, norethisterone enanthate (NET-EN) given at 60-

day intervals for the entire study period (NET-EN [60-day]), and NET-EN given at 60-day intervals for 6 months and

thereafter at 84-day intervals (NET-EN [84-day]). 1587 DMPA subjects were observed for 20,550 woman-months, 789

NET-EN (60-day) subjects were observed for 10,361 woman-months, and 796 subjects NET-EN [84-day] were

observed for 10,331 woman-months. This clinical trial represents the largest clinical trial undertaken on injectable

contraceptives. After 2 years, the pregnancy rate with NET-EN (84-day) was 1.4 (+or- 0.6 S.E.)/100 women, as

compared with the 2 year rates of 0.4 (+or- 0.3 S.E.)/100 women observed with DMPA and 0.4 (+or- 0.2 S.E.) with

NET-EN (60-day). Both discontinuation rates for amenorrhea and the prevalence of amenorrhea lasting more than 90

days were significantly higher with DMPA than with either NET-EN regimen. Terminations for bleeding problems

were similar with the 3 treatments, despite a better cyclic pattern for the 1st 6 months with the NET-EN regimens.

The 3 treatments were comparable with respect to discontinuation rates for other medical or personal reasons, and

for all reasons combined. 4 deaths were reported among study subjects. 1 woman died of metastatic

choriocarcinoma, 1 of tuberculosis, and 2 suddenly--1 apparently of tuberculosis, and the other of undetermined

causes. None of the deaths appeared to be drug-related. For family planning programs, NET-EN (60-day) has the

advantage of low pregnancy rates compared to NET-EN (84-day), and a schedule of administration that does not

change. Both regimens with NET-EN produce less amenorrhea than DMPA. However, the NET-EN (60-day) regimen

has the logistic and economic disadvantage of requiring more frequent injections. All 3 injectable regimens

compare favorably with OCs in terms of pregnancy and total continuation rates observed in clinical trail settings.

(author's) (PubHealth.info Document ID: CONT5T 2005-06)

PubHealth.info NOTE: The author(s) of this article titled, "Multinational comparative clinical trial of long-acting

injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone

acetate: final report.", is(are) World Health Organization [WHO]. Special Programme of Research, Development and

Research Training in Human Reproduction. Task Force on Long-Acting Systemic Agents for Fertility Regulation. The

source of this article is "[Unpublished] [1983]. 21 p.". This article was published in 1983 in English language(s).

(PubHealth.info® Document ID: CONT5T 2005-06. All rights reserved with PubHealth.info) PIN: 22005

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.